Early trial aims to make brain tumors more vulnerable to radiation
NCT ID NCT02015117
Summary
This early-stage study is testing whether a drug called trametinib can be safely combined with whole brain radiation therapy for patients whose cancer has spread to the brain. The goal is to see if the drug makes the tumor cells more sensitive to the radiation, potentially improving treatment. Researchers will find the safest dose and see how well the combination works in a small group of patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM IN THE BRAIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.